NASDAQ:IMV

IMV Competitors

$2.68
0.00 (0.00 %)
(As of 04/20/2021 04:40 PM ET)
Add
Compare
Today's Range
$2.63
Now: $2.68
$2.72
50-Day Range
$2.73
MA: $3.18
$3.90
52-Week Range
$1.73
Now: $2.68
$6.82
Volume141,373 shs
Average Volume264,465 shs
Market Capitalization$181.24 million
P/E RatioN/A
Dividend YieldN/A
Beta1.69

Competitors

IMV (NASDAQ:IMV) Vs. XENE, LXRX, KPTI, ZIOP, CALT, and ICPT

Should you be buying IMV stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to IMV, including Xenon Pharmaceuticals (XENE), Lexicon Pharmaceuticals (LXRX), Karyopharm Therapeutics (KPTI), ZIOPHARM Oncology (ZIOP), Calliditas Therapeutics AB (publ) (CALT), and Intercept Pharmaceuticals (ICPT).

IMV (NASDAQ:IMV) and Xenon Pharmaceuticals (NASDAQ:XENE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk and institutional ownership.

Institutional & Insider Ownership

20.7% of IMV shares are owned by institutional investors. Comparatively, 79.9% of Xenon Pharmaceuticals shares are owned by institutional investors. 8.4% of Xenon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk & Volatility

IMV has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500. Comparatively, Xenon Pharmaceuticals has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500.

Profitability

This table compares IMV and Xenon Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IMV-9,661.54%-180.04%-91.98%
Xenon Pharmaceuticals-102.25%-21.76%-16.08%

Earnings and Valuation

This table compares IMV and Xenon Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMV$430,000.00421.50$-20,620,000.00($0.41)-6.54
Xenon Pharmaceuticals$6.83 million97.26$-41,600,000.00($1.54)-12.05

IMV has higher earnings, but lower revenue than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than IMV, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for IMV and Xenon Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IMV03402.57
Xenon Pharmaceuticals00503.00

IMV currently has a consensus price target of $8.5417, suggesting a potential upside of 218.72%. Xenon Pharmaceuticals has a consensus price target of $25.25, suggesting a potential upside of 36.12%. Given IMV's higher probable upside, analysts clearly believe IMV is more favorable than Xenon Pharmaceuticals.

Summary

Xenon Pharmaceuticals beats IMV on 8 of the 14 factors compared between the two stocks.

IMV (NASDAQ:IMV) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.

Institutional and Insider Ownership

20.7% of IMV shares are owned by institutional investors. Comparatively, 84.6% of Lexicon Pharmaceuticals shares are owned by institutional investors. 6.4% of Lexicon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

IMV has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500. Comparatively, Lexicon Pharmaceuticals has a beta of 2.09, suggesting that its stock price is 109% more volatile than the S&P 500.

Profitability

This table compares IMV and Lexicon Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IMV-9,661.54%-180.04%-91.98%
Lexicon Pharmaceuticals-320.44%-164.96%-31.83%

Earnings & Valuation

This table compares IMV and Lexicon Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMV$430,000.00421.50$-20,620,000.00($0.41)-6.54
Lexicon Pharmaceuticals$322.07 million2.19$130.13 million$1.353.61

Lexicon Pharmaceuticals has higher revenue and earnings than IMV. IMV is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for IMV and Lexicon Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IMV03402.57
Lexicon Pharmaceuticals06202.25

IMV currently has a consensus price target of $8.5417, suggesting a potential upside of 218.72%. Lexicon Pharmaceuticals has a consensus price target of $9.40, suggesting a potential upside of 93.42%. Given IMV's stronger consensus rating and higher probable upside, equities research analysts plainly believe IMV is more favorable than Lexicon Pharmaceuticals.

Summary

Lexicon Pharmaceuticals beats IMV on 10 of the 14 factors compared between the two stocks.

IMV (NASDAQ:IMV) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.

Institutional and Insider Ownership

20.7% of IMV shares are owned by institutional investors. Comparatively, 88.6% of Karyopharm Therapeutics shares are owned by institutional investors. 13.3% of Karyopharm Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

IMV has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500. Comparatively, Karyopharm Therapeutics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500.

Profitability

This table compares IMV and Karyopharm Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IMV-9,661.54%-180.04%-91.98%
Karyopharm Therapeutics-221.23%-187.66%-56.42%

Earnings & Valuation

This table compares IMV and Karyopharm Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMV$430,000.00421.50$-20,620,000.00($0.41)-6.54
Karyopharm Therapeutics$40.89 million17.33$-199,590,000.00($3.22)-2.93

IMV has higher earnings, but lower revenue than Karyopharm Therapeutics. IMV is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for IMV and Karyopharm Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IMV03402.57
Karyopharm Therapeutics01802.89

IMV currently has a consensus price target of $8.5417, suggesting a potential upside of 218.72%. Karyopharm Therapeutics has a consensus price target of $29.8750, suggesting a potential upside of 216.81%. Given IMV's higher probable upside, equities research analysts plainly believe IMV is more favorable than Karyopharm Therapeutics.

Summary

Karyopharm Therapeutics beats IMV on 8 of the 14 factors compared between the two stocks.

IMV (NASDAQ:IMV) and ZIOPHARM Oncology (NASDAQ:ZIOP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.

Institutional and Insider Ownership

20.7% of IMV shares are owned by institutional investors. Comparatively, 48.0% of ZIOPHARM Oncology shares are owned by institutional investors. 2.3% of ZIOPHARM Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

IMV has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500. Comparatively, ZIOPHARM Oncology has a beta of 2.28, suggesting that its stock price is 128% more volatile than the S&P 500.

Profitability

This table compares IMV and ZIOPHARM Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IMV-9,661.54%-180.04%-91.98%
ZIOPHARM OncologyN/A-48.49%-43.53%

Earnings & Valuation

This table compares IMV and ZIOPHARM Oncology's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMV$430,000.00421.50$-20,620,000.00($0.41)-6.54
ZIOPHARM Oncology$150,000.004,548.00$-117,800,000.00($0.34)-9.32

IMV has higher revenue and earnings than ZIOPHARM Oncology. ZIOPHARM Oncology is trading at a lower price-to-earnings ratio than IMV, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for IMV and ZIOPHARM Oncology, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IMV03402.57
ZIOPHARM Oncology03202.40

IMV currently has a consensus price target of $8.5417, suggesting a potential upside of 218.72%. ZIOPHARM Oncology has a consensus price target of $5.90, suggesting a potential upside of 86.71%. Given IMV's stronger consensus rating and higher probable upside, equities research analysts plainly believe IMV is more favorable than ZIOPHARM Oncology.

Summary

ZIOPHARM Oncology beats IMV on 9 of the 14 factors compared between the two stocks.

IMV (NASDAQ:IMV) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.

Institutional and Insider Ownership

20.7% of IMV shares are owned by institutional investors. Comparatively, 11.9% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares IMV and Calliditas Therapeutics AB (publ)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IMV-9,661.54%-180.04%-91.98%
Calliditas Therapeutics AB (publ)N/A-26.80%-25.38%

Earnings & Valuation

This table compares IMV and Calliditas Therapeutics AB (publ)'s top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMV$430,000.00421.50$-20,620,000.00($0.41)-6.54
Calliditas Therapeutics AB (publ)$19.56 million33.22$-3,450,000.00($0.19)-136.95

Calliditas Therapeutics AB (publ) has higher revenue and earnings than IMV. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than IMV, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for IMV and Calliditas Therapeutics AB (publ), as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IMV03402.57
Calliditas Therapeutics AB (publ)00503.00

IMV currently has a consensus price target of $8.5417, suggesting a potential upside of 218.72%. Calliditas Therapeutics AB (publ) has a consensus price target of $40.80, suggesting a potential upside of 56.92%. Given IMV's higher probable upside, equities research analysts plainly believe IMV is more favorable than Calliditas Therapeutics AB (publ).

Summary

Calliditas Therapeutics AB (publ) beats IMV on 8 of the 12 factors compared between the two stocks.

IMV (NASDAQ:IMV) and Intercept Pharmaceuticals (NASDAQ:ICPT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.

Analyst Recommendations

This is a summary of recent recommendations for IMV and Intercept Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IMV03402.57
Intercept Pharmaceuticals115802.29

IMV currently has a consensus price target of $8.5417, suggesting a potential upside of 218.72%. Intercept Pharmaceuticals has a consensus price target of $50.6957, suggesting a potential upside of 144.08%. Given IMV's stronger consensus rating and higher probable upside, equities research analysts plainly believe IMV is more favorable than Intercept Pharmaceuticals.

Volatility & Risk

IMV has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500. Comparatively, Intercept Pharmaceuticals has a beta of 1.85, suggesting that its stock price is 85% more volatile than the S&P 500.

Institutional and Insider Ownership

20.7% of IMV shares are owned by institutional investors. Comparatively, 85.8% of Intercept Pharmaceuticals shares are owned by institutional investors. 23.7% of Intercept Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares IMV and Intercept Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IMV-9,661.54%-180.04%-91.98%
Intercept Pharmaceuticals-106.64%-1,973.10%-48.51%

Earnings & Valuation

This table compares IMV and Intercept Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMV$430,000.00421.50$-20,620,000.00($0.41)-6.54
Intercept Pharmaceuticals$252 million2.74$-344,680,000.00($10.89)-1.91

IMV has higher earnings, but lower revenue than Intercept Pharmaceuticals. IMV is trading at a lower price-to-earnings ratio than Intercept Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Intercept Pharmaceuticals beats IMV on 8 of the 14 factors compared between the two stocks.


IMV Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Xenon Pharmaceuticals logo
XENE
Xenon Pharmaceuticals
1.6$18.55flat$709.73 million$6.83 million-19.12
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$4.88flat$698.67 million$322.07 million-4.65Upcoming Earnings
Decrease in Short Interest
News Coverage
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.7$9.44flat$692.81 million$40.89 million-3.26News Coverage
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.17flat$675.74 million$150,000.00-4.53News Coverage
Calliditas Therapeutics AB (publ) logo
CALT
Calliditas Therapeutics AB (publ)
1.4$26.02flat$671.97 million$19.56 million-18.72
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$20.80flat$666.59 million$252 million-2.13
Chimerix logo
CMRX
Chimerix
1.3$7.91flat$665.73 million$12.52 million-13.88
VBI Vaccines logo
VBIV
VBI Vaccines
1.5$2.61flat$662.95 million$2.22 million-15.35News Coverage
Veru logo
VERU
Veru
1.4$8.88flat$653.68 million$42.59 million-31.71Analyst Report
Chinook Therapeutics logo
KDNY
Chinook Therapeutics
1.4$14.67flat$650.06 million$17.26 million-4.08
Bicycle Therapeutics logo
BCYC
Bicycle Therapeutics
1.3$29.32flat$648.83 million$13.80 million-14.16Analyst Report
News Coverage
Kadmon logo
KDMN
Kadmon
1.8$3.83flat$637.44 million$5.09 million-6.38
Gossamer Bio logo
GOSS
Gossamer Bio
1.7$8.20flat$632.17 millionN/A-2.30Increase in Short Interest
News Coverage
Albireo Pharma logo
ALBO
Albireo Pharma
1.5$31.51flat$628.85 million$9.64 million-5.13
Evelo Biosciences logo
EVLO
Evelo Biosciences
1.9$10.84flat$616.02 millionN/A-4.35Analyst Upgrade
News Coverage
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.67flat$604.18 million$143.01 million-1.08
OrganiGram logo
OGI
OrganiGram
1.6$2.34flat$603.91 million$64.61 million-3.44Analyst Downgrade
Decrease in Short Interest
Gap Down
AnaptysBio logo
ANAB
AnaptysBio
1.5$21.91flat$595.21 million$8 million-8.08
IDEAYA Biosciences logo
IDYA
IDEAYA Biosciences
1.5$18.56flat$592.94 millionN/A-9.87Analyst Report
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.55flat$591.17 million$59.29 million-23.67Increase in Short Interest
News Coverage
Relmada Therapeutics logo
RLMD
Relmada Therapeutics
1.1$34.67flat$577.60 millionN/A-16.05
KalVista Pharmaceuticals logo
KALV
KalVista Pharmaceuticals
1.8$23.61flat$573.91 million$12.69 million-11.35Increase in Short Interest
News Coverage
Gap Up
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.2$42.87flat$563.31 million$195.89 million122.49
SIGA Technologies logo
SIGA
SIGA Technologies
0.3$7.57flat$551.05 million$26.74 million18.93News Coverage
Mirum Pharmaceuticals logo
MIRM
Mirum Pharmaceuticals
1.8$17.86flat$547.04 millionN/A-5.19
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.8$16.55flat$534.08 million$1.19 million-6.90
Urovant Sciences logo
UROV
Urovant Sciences
0.7$16.24flat$531.75 millionN/A-3.15
IVERIC bio logo
ISEE
IVERIC bio
1.5$5.84flat$521.18 millionN/A-4.63News Coverage
Aldeyra Therapeutics logo
ALDX
Aldeyra Therapeutics
1.4$11.02flat$518.23 millionN/A-8.54
Inventiva logo
IVA
Inventiva
0.0$13.27flat$517.26 millionN/A0.00
Marinus Pharmaceuticals logo
MRNS
Marinus Pharmaceuticals
1.7$13.85flat$513.60 millionN/A-3.99
Neoleukin Therapeutics logo
NLTX
Neoleukin Therapeutics
1.4$12.04flat$510.88 million$25 million-18.52
Provention Bio logo
PRVB
Provention Bio
1.6$7.81flat$510.17 millionN/A-5.24Analyst Report
Increase in Short Interest
Magenta Therapeutics logo
MGTA
Magenta Therapeutics
1.3$10.61flat$509.84 millionN/A-5.44
89bio logo
ETNB
89bio
1.6$25.81flat$505.03 millionN/A-5.11Insider Selling
RAPT Therapeutics logo
RAPT
RAPT Therapeutics
1.6$20.64flat$498.07 millionN/A-8.13
Avadel Pharmaceuticals logo
AVDL
Avadel Pharmaceuticals
1.5$8.18flat$495.20 million$59.22 million40.90
XBiotech logo
XBIT
XBiotech
1.0$16.48flat$493.73 millionN/A1.14News Coverage
Amryt Pharma logo
AMYT
Amryt Pharma
1.4$13.50flat$493.31 million$58.12 million-15.70
CytomX Therapeutics logo
CTMX
CytomX Therapeutics
1.6$7.96flat$492.36 million$57.49 million-6.69News Coverage
Gap Up
Akouos logo
AKUS
Akouos
1.6$14.60flat$490.23 millionN/A0.00
Forte Biosciences logo
FBRX
Forte Biosciences
1.7$33.20flat$483.22 million$40,000.00-1.44Upcoming Earnings
Gap Up
AC Immune logo
ACIU
AC Immune
1.3$6.51flat$468.31 million$111.75 million-7.23Analyst Upgrade
Analyst Revision
Gap Up
Molecular Templates logo
MTEM
Molecular Templates
2.0$7.96flat$464.67 million$22.27 million-3.90Analyst Revision
News Coverage
Evolus logo
EOLS
Evolus
1.5$10.55flat$464.44 million$34.92 million-5.20Gap Up
Verastem logo
VSTM
Verastem
1.3$2.71flat$463.50 million$17.46 million-1.92
TherapeuticsMD logo
TXMD
TherapeuticsMD
1.5$1.17flat$456.10 million$49.65 million-1.65
Verona Pharma logo
VRNA
Verona Pharma
1.7$7.58flat$448.42 millionN/A-2.30
Viking Therapeutics logo
VKTX
Viking Therapeutics
1.6$5.81flat$448.40 millionN/A-11.86News Coverage
Catalyst Pharmaceuticals logo
CPRX
Catalyst Pharmaceuticals
1.7$4.39flat$447.49 million$102.31 million6.55Increase in Short Interest
News Coverage
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.